tiprankstipranks
Trending News
More News >
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
US Market

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Compare
1,274 Followers
See the Price Targets and Ratings of:

CAPR Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Capricor
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAPR Stock 12 Month Forecast

Average Price Target

$54.88
▲(79.93% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $54.88 with a high forecast of $63.00 and a low forecast of $41.00. The average price target represents a 79.93% change from the last price of $30.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","64":"$64","19.75":"$19.75","34.5":"$34.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$63.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,19.75,34.5,49.25,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,29.64,32.42,35.2,37.980000000000004,40.760000000000005,43.54,46.32,49.1,51.88,54.660000000000004,57.44,60.22,{"y":63,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,29.015384615384615,31.17076923076923,33.326153846153844,35.48153846153846,37.636923076923075,39.79230769230769,41.94769230769231,44.10307692307693,46.25846153846154,48.41384615384615,50.56923076923077,52.72461538461538,{"y":54.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.86,27.947692307692307,29.035384615384615,30.123076923076923,31.21076923076923,32.29846153846154,33.386153846153846,34.473846153846154,35.56153846153846,36.64923076923077,37.73692307692308,38.824615384615385,39.91230769230769,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 73, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 64, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$63.00Average Price Target$54.88Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CAPR
H.C. Wainwright
H.C. Wainwright
$60
Buy
96.72%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Capricor Therapeutics (NASDAQ: CAPR)
B. Riley Securities Analyst forecast on CAPR
B. Riley Securities
B. Riley Securities
$50$63
Buy
106.56%
Upside
Assigned
03/13/26
B. Riley Securities Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
Piper Sandler Analyst forecast on CAPR
Piper Sandler
Piper Sandler
$45$58
Buy
90.16%
Upside
Reiterated
03/13/26
Piper Sandler Remains a Buy on Capricor Therapeutics (CAPR)
Alliance Global Partners Analyst forecast on CAPR
Unknown Analyst
Alliance Global Partners
Not Ranked
Alliance Global Partners
$48$51
Buy
67.21%
Upside
Reiterated
03/13/26
Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
Roth MKM
$41
Buy
34.43%
Upside
Reiterated
03/12/26
Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)
Oppenheimer Analyst forecast on CAPR
Oppenheimer
Oppenheimer
$54
Buy
77.05%
Upside
Reiterated
03/12/26
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)
Cantor Fitzgerald Analyst forecast on CAPR
Cantor Fitzgerald
Cantor Fitzgerald
$62
Buy
103.28%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR)
Maxim Group Analyst forecast on CAPR
Maxim Group
Maxim Group
$50
Buy
63.93%
Upside
Reiterated
03/11/26
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
JonesTrading Analyst forecast on CAPR
JonesTrading
JonesTrading
$29
Buy
-4.92%
Downside
Reiterated
09/25/25
Capricor approval on track for mid-2026, says JonesResearchCapricor approval on track for mid-2026, says JonesResearch
Ladenburg Thalmann & Co. Analyst forecast on CAPR
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$48
Buy
57.38%
Upside
Reiterated
03/20/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CAPR
H.C. Wainwright
H.C. Wainwright
$60
Buy
96.72%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Medtronic (NYSE: MDT) and Capricor Therapeutics (NASDAQ: CAPR)
B. Riley Securities Analyst forecast on CAPR
B. Riley Securities
B. Riley Securities
$50$63
Buy
106.56%
Upside
Assigned
03/13/26
B. Riley Securities Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)
Piper Sandler Analyst forecast on CAPR
Piper Sandler
Piper Sandler
$45$58
Buy
90.16%
Upside
Reiterated
03/13/26
Piper Sandler Remains a Buy on Capricor Therapeutics (CAPR)
Alliance Global Partners Analyst forecast on CAPR
Unknown Analyst
Alliance Global Partners
Not Ranked
Alliance Global Partners
$48$51
Buy
67.21%
Upside
Reiterated
03/13/26
Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
Roth MKM
$41
Buy
34.43%
Upside
Reiterated
03/12/26
Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)
Oppenheimer Analyst forecast on CAPR
Oppenheimer
Oppenheimer
$54
Buy
77.05%
Upside
Reiterated
03/12/26
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)
Cantor Fitzgerald Analyst forecast on CAPR
Cantor Fitzgerald
Cantor Fitzgerald
$62
Buy
103.28%
Upside
Reiterated
03/11/26
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR)
Maxim Group Analyst forecast on CAPR
Maxim Group
Maxim Group
$50
Buy
63.93%
Upside
Reiterated
03/11/26
Deramiocel’s De‑Risked Path to Approval and Expanded DMD Opportunity Underpin Buy on CAPR
JonesTrading Analyst forecast on CAPR
JonesTrading
JonesTrading
$29
Buy
-4.92%
Downside
Reiterated
09/25/25
Capricor approval on track for mid-2026, says JonesResearchCapricor approval on track for mid-2026, says JonesResearch
Ladenburg Thalmann & Co. Analyst forecast on CAPR
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$48
Buy
57.38%
Upside
Reiterated
03/20/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Capricor Therapeutics

3 Months
xxx
Success Rate
5/11 ratings generated profit
45%
Average Return
+39.03%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +39.03% per trade.
1 Year
Jason McCarthyMaxim Group
Not Ranked
Success Rate
13/15 ratings generated profit
87%
Average Return
+147.50%
reiterated a buy rating 6 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +147.50% per trade.
2 Years
xxx
Success Rate
15/16 ratings generated profit
94%
Average Return
+256.80%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.75% of your transactions generating a profit, with an average return of +256.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAPR Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
15
16
19
12
5
Buy
0
3
5
5
4
Hold
31
42
73
64
48
Sell
10
10
4
0
0
Strong Sell
0
0
0
0
0
total
56
71
101
81
57
In the current month, CAPR has received 9 Buy Ratings, 48 Hold Ratings, and 0 Sell Ratings. CAPR average Analyst price target in the past 3 months is 54.88.
Each month's total comprises the sum of three months' worth of ratings.

CAPR Financial Forecast

CAPR Earnings Forecast

Next quarter’s earnings estimate for CAPR is -$0.52 with a range of -$0.63 to -$0.38. The previous quarter’s EPS was -$0.62. CAPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.
Next quarter’s earnings estimate for CAPR is -$0.52 with a range of -$0.63 to -$0.38. The previous quarter’s EPS was -$0.62. CAPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Sales Forecast

Next quarter’s sales forecast for CAPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.
Next quarter’s sales forecast for CAPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Stock Forecast FAQ

What is CAPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics’s 12-month average price target is 54.88.
    What is CAPR’s upside potential, based on the analysts’ average price target?
    Capricor Therapeutics has 79.93% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CAPR a Buy, Sell or Hold?
          Capricor Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Capricor Therapeutics’s price target?
            The average price target for Capricor Therapeutics is 54.88. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $63.00 ,the lowest forecast is $41.00. The average price target represents 79.93% Increase from the current price of $30.5.
              What do analysts say about Capricor Therapeutics?
              Capricor Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of CAPR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.